Strategies for the treatment of acute myeloid leukemia with FLT3 mutations: a patent review
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10492346" target="_blank" >RIV/00179906:_____/25:10492346 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15310/25:73627215 RIV/60162694:G44__/26:00564830 RIV/00216208:11150/25:10492346 RIV/00216208:11160/25:10492346
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=asIMvaGxKh" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=asIMvaGxKh</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/13543776.2024.2446224" target="_blank" >10.1080/13543776.2024.2446224</a>
Alternative languages
Result language
angličtina
Original language name
Strategies for the treatment of acute myeloid leukemia with FLT3 mutations: a patent review
Original language description
Introduction: Approximately one-third of all AML patients have a mutation in the Fms-like tyrosine kinase 3 (FLT3) gene, which is associated with a poor prognosis in these individuals. The 2017 approval of midostaurin, the first FLT3 inhibitor, spurred extensive development of more potent and selective inhibitors with an improved safety profile. Areas covered: This review analyzes patent inventions for the treatment of AML using FLT3 inhibitors, covering developments from the earliest to the most recent, disclosed in 2024. Our search using the global Espacenet database identified numerous compounds with low nanomolar inhibitory concentrations against FLT3-ITD and FLT3-TKD mutants. These compounds have shown promise in preclinical studies. Co-inhibition strategies and combinatorial therapies to overcome resistance and enhance anti-leukemic efficacy are also discussed. Expert opinion: Recent patents highlight advances in the field of FLT3 inhibitors with a focus on overcoming resistance, improving selectivity and potency. Future strategies may include third-generation inhibitors such as type III allosteric inhibitors, irreversible inhibitors, or PROTACs. Personalized medicine approaches utilizing genetic profiling to tailor therapies are emphasized. Exploration of novel combination regimens with emerging therapies like CAR T-cell therapy, immune checkpoint inhibitors, and small molecules targeting critical AML pathways is ongoing to further enhance anti-leukemic efficacy.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Expert Opinion on Therapeutic Patents
ISSN
1354-3776
e-ISSN
1744-7674
Volume of the periodical
35
Issue of the periodical within the volume
2
Country of publishing house
GB - UNITED KINGDOM
Number of pages
28
Pages from-to
137-164
UT code for WoS article
001391169100001
EID of the result in the Scopus database
2-s2.0-85214473851